Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brivudine - Berlin Chemie

Drug Profile

Brivudine - Berlin Chemie

Alternative Names: Brivudin; Bromovinyldeoxyuridine; BVDU; Zostex

Latest Information Update: 06 Oct 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Berlin Chemie
  • Class Adjuvants; Antivirals; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Herpes zoster
  • Discontinued Cancer; Herpes simplex virus infections; Varicella zoster virus infections

Most Recent Events

  • 26 Apr 2001 Two phase III trials have been added to the Viral Infections therapeutic trials and adverse events sections
  • 26 Mar 2001 Phase-III clinical trials for Herpes zoster in Europe (PO)
  • 26 Mar 2001 Phase-III clinical trials for Herpes zoster in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top